Over the past few decades, heparin and heparan sulfate have been shown to interact with a number of biologically important proteins, thereby playing an essential role in the regulation of various physiological processes (1, 2) . The understanding of these interactions at the molecular level is important for the design of new highly specific therapeutic agents. In addition, better knowledge of specificity of heparin and heparan sulfate will be necessary to understand normal physiologic and pathophysiologic processes. Most heparin-protein interactions involve ion pairing or hydrogen bonding between basic or hydrogen bonding groups on the protein and charged sulfo or carboxyl groups on heparin (1). Very few heparin-protein interactions are modified through divalent ions such as calcium.
modeling of heparin-protein interactions (5) (6) (7) (8) (9) . Recently, Eckert and Ragg reported that Zn 2+and to a lesser extent Cu 2+ and Ni 2+ -enhanced the interaction between heparin cofactor II and heparin as demonstrated by heparin affinity chromatography and surface plasmon resonance experiments (9) . They suggested that Zn 2+ induces a conformational change in heparin cofactor II that favors its interaction with heparin. Other researchers had previously shown that calcium spirulan (Ca-SP), a novel sulfated polysaccharide isolated from a bluegreen alga Spiraling platensis, enhanced the rate of inhibition of thrombin by HCII. This group also reported that the molecular conformation required for its antithrombin activity is maintained by calcium ions (10) .
In the present study, SPR was applied to quantitative study of heparin-HCII interactions. A heparin biochip in which heparin was covalently immobilized through a preformed albumin-heparin conjugate was used in these studies. The interactions of HCII with heparin, low-molecular-weight (LMW) heparin, and heparin oligosaccharides (disaccharide, tetrasaccharide, hexasaccharide) were examined by solution competition SPR, and the influence of calcium on the heparin/HCII interaction was also evaluated.
MATERIALS AND METHODS

Materials
Heparin cofactor II (HCII, MW: 66,000) was a product purified from human plasma by Diagnostica Stago (France) and showed a single band on sodium dodecyl sulfate polyacryamide gel electrophoresis (SDS-PAGE). Heparin (MW: 14,000) from porcine intestinal mucosa, sodium salts, was prepared by Celsus Laboratories (Cincinnati, OH). LMW heparin from porcine intestinal mucosa, sodium salt (MW: 5,000) prepared using nitrous acid was purchased from Calbiochem-Novabiochemi Corporation (La Jolla, CA (NHS) and N-ethyl-N-(dimethyaminopropyl) carbodiimide (EDC) were obtained from BIAcore (Biosensor AB, Uppsala, Sweden). Bovine serum albumin (BSA) was obtained from Amresco (Solon, Ohio). Albumin-heparin conjugate and other chemicals were obtained from Sigma-Aldrich Co. (St. Louis, MO) and were of the highest purity commercially available. SPR experiments were performed on the BIAcore 3000 apparatus operated using BIAcore 3000 version software. Buffers used in SPR were filtered and degassed.
Preparation and Characterization of Heparin-Derived Oligosaccharides
Heparin (10 g) in 160 mL of 50 mM sodium phosphate buffer (pH 7.0) containing 2 mg/mL BSA was sterile-filtered through a 0.22-µm filter unit. With the addition of heparin lyase I (92 mU, was added twice at 0 and 24 h), the digestion was carried out at 30°C. When the absorbance at 232 nm indicated that the digestion was 30% completed, the digestion was stopped by heating at 100°C for 1 minute to inactivate the enzyme. Undigested heparin was removed by ultra-filtration with a membrane (5000 MWCO). Next, the LMW heparin oligosaccharides (MW< 5000) mixture obtained was fractionated on a Bio-Gel P-6 column (4.8 × 100 cm) using 200 mM sodium chloride as the running buffer. Fractions consisting of disaccharides, tetrasaccharides, hexasaccharides, octasaccharides, and higher oligosaccharides were obtained for the further purification.
Before HPLC purification, samples of molecular weight less than 2000 (disaccharide, tetrasaccharide, hexasaccharide, and octasaccharides) were desalted on a Sephadex G-10 column. Charge separation of the sized oligosaccharides was then carried out by a semi-preparative SAX-HPLC on a 5-µM, 0.46 × 25 cm column (Waters) using a linear gradient from 0.2 to 2 M of sodium chloride (pH 3.5) at a flow rate of 1.0 mL/min. The major peaks were pooled, freeze-dried, and desalted with Sephadex G-10 column. The purified oligosaccharides were analyzed by analytical SAX-HPLC, capillary electrophoresis (CE), gradient PAGE, and 1 H NMR to confirm the purity and structures of each oligosaccharide.
Preparation of Heparin Biochip
Heparin biochip was prepared by covalently immobilizing albumin-heparin conjugate to biosensor surface through its primary amino groups on C1 chip (11) . Briefly, carboxymethyl groups on the C1 Chip surface were first activated using an injection pulse of 50 µL (flow rate, 5 µL/min) of an equimolar mix of NHS/EDC (final concentration 0.05 M, mixed immediately before injection). An albumin-heparin solution (200 µg/mL in sodium acetate buffer with 2 M guanadine hydrochloride, pH 4.0) was applied to the chip surface. Excess unreacted sites on the sensor surface were blocked with a 40 µL injection of 1 M ethanolamine. Successful immobilization was confirmed by the observation of an approximate 300 RU response increase. To prepare the control flow cell, bovine serum was immobilized on the surface using a similar coupling procedure.
Kinetic Measurements of Heparin and HCII Interaction
Different concentrations of HCII in phosphate buffer saline (PBS), (50 mM sodium phosphate buffer, 150 mM NaCl, pH 7.4) was injected over both the albumin-heparin and control albumin surfaces simultaneously at a flow rate of 10 µL/min. At the end of each sample injection, the same buffer was flowed over the sensor surface to facilitate dissociation studies. After a suitable dissociation time (3 minutes), the sensor surface was regenerated with injections of 20 µL of 2 M NaCl, 20 µL glycine (pH 2.0), 20 µL NaOH (pH 10.0), and 20 µL PBS buffer. The response was monitored as a function of time (sensogram) at 25°C. The control cell was used to subtract the contribution of nonspecific interactions with the immobilized albumin on the surface itself. Kinetic parameters were evaluated using BIA evaluation software (version 3.1, 1999).
Solution Competition Study Between HCII and Heparin, LMW Heparin, and Oligosaccharides
HCII (15 µM) mixed with different concentrations of heparin, LMW heparin, disaccharide, tetrasaccharide and hexasaccharide (30 µL) were injected over both the albumin-heparin and the control albumin surfaces at a flow rate of 10 µL/min. After each run, the dissociation and the regeneration were performed as described previously. For each set of competition experiments on SPR, a control experiment (only HCII without any heparin or oligosaccharides) was performed to make sure the surface was completely regenerated and that the results obtained between runs were comparable.
Anti-Protease Activity Assay of Heparin Oligosaccharides
The ability of an agent to mediate antiprotease activity via HCII (12) was measured with an amidolytic substrate assay run on the ACL fast kinetics analyzer (Hialeah, FL). Test agents (100 µg/mL) were prepared in saline. 4.2 µL of a 500 µg/mL human HCII solution was added to the sample cups so that the final concentration of HCII in the assay was 8.4 µg/mL. The first reagent consisted of human factor IIa (8.5 NIH unit/mL, Enzyme Research Laboratory, South Bend, IN) in buffer (50 mM Tris, 175 mM NaCl, 7.5 mM EDTA, pH=8.5, 25°C). The second reagent consisted of 0.625 mM Spectrozyme TH (American Diagnostica Inc., Greenwich, CT). The instrument was programmed so that 100 µL of sample and 50 µL of reagent 1 were placed into individual compartments in a reaction rotor. These reagents were and incubated at 37°C for 1 minute and were then mixed together. One hundred microliters of reagent 2 was then added to the rotor and the rotor was spun at 1200 rpm. Optical density readings at 405 nm were made continuously for 1 minute (A 405 /min). The change in optical density with time was used to calculate percent inhibition of factor IIa.
RESULTS
Sequence Analysis of HCII
EF-hand motifs ( Table 1) are among the most well-studied calcium binding domains in the proteins (16) . The sequence of human HCII ( Fig. 1 ) was searched for the presence of EF-hand motifs. Three sequences (CB-1, 2, and 3) closely matching the EF-hand motifs were found in the HCII sequence (Table 1 ), suggesting calcium may bind to HCII enhancing its interaction with heparin and possibly affecting its activity against thrombin. The canonical EF-hand consists of an α-helix, a loop wrapped around the Ca 2+ ion, and a second αhelix. The numbers given represent the positions of amino acids in the loop region. The letters, X, Y, Z, -X, Y, and -Z, represent amino acid residues that coordinate to the Ca 2+ ion. CB-1(aa337-348), CB-2(aa418-430) and CB-3(aa436-447) of HCII were aligned well with the consensus sequence for calcium-binding EF-hands (14, 16) . The consensus sequence shown at the bottom of Table 1 lists amino acids (in boldface) that have been observed among various calcium binding proteins by decreasing order of frequency.
Kinetic Measurements of Heparin and HCII Interaction
Sensograms for the binding of HCII to immobilized heparin in the absence of calcium ion are shown in Fig. 2 . The initial portion of each curve (< 0 seconds) represents buffer flowing past the sensor face. The second and rising part of each curve (10-200 seconds) corresponds to the response of the sensor surface observed as a sample injection volume containing protein flows past and binds to the immobilized heparin. The final portion of the curves (205-225 seconds) corresponds to the dissociation of bound protein after the sample volume has finished and buffer flows past and binds to the immobilized heparin. The peaks at 0 seconds correspond to the injection front and at 200-205 seconds correspond to the change in the RU associated with switching to wash buffer. They are artifacts common to SPR and are not used in the calculation of con-stants. The dissociation rate constant, k d , was evaluated from each trace and used to calculate the observed association rate constant, k a . The ratio k a /k d generates the overall association constant or disassociation constant K d . The binding curves are relatively steep in the association phase, which suggests a high affinity of HCII to heparin and a quick association phase. The disassociation curves show slow disassociation, indicating that the binding is strong. Kinetic analysis of the interaction between HCII and heparin afforded a k d value of 7.37 × 10 -4 s -1 , a k a value of 241 M/s and a K d of 3.03 × 10 -6 M ( Table 2) . Hand Homology  1  2  3  4  5  6  7  8  9  10  11 
Sequence of HCII (total 499 amino acids). The CB-1, CB-2, and CB-3 binding motifs are bold and underlined.
The Effect of Calcium Ion on Heparin Interaction with HCII
Identical SPR experiments were performed in the presence of 1 mM calcium chloride (Fig. 3) . Interestingly, the sensorgrams showed that with calcium ion present the maximum HCII binding (RU) changes were higher for each curve than those obtained in the absence of calcium. Kinetic analysis of the interaction between HCII and heparin in the presence of calcium ions afforded a k d value of 8.97 × 10 -5 s -1 , a k a value of 520 M/s, and a K d of 2.23 × 10 -7 M. This K d is nearly 10fold higher than the K d obtained in the absence of calcium ions ( Table 1 ). The 10-fold increase in K d is due mostly to a decrease in k d . The k a value was not significantly different (only twofold) when determined in the presence and absence of calcium ions.
Solution Competition Studies Using Heparin, LMW Heparin, and Heparin-Derived Oligosaccharides
To examine the effect of saccharide chain size of heparin on the HCII interaction, solution/surface competition experiments were performed by SPR. In each competition experiment, different amounts of heparin, LMW heparin, and heparinderived disaccharide and tetrasaccharide and hexasaccaride of defined structures (Fig. 4A) were added in the analyte (HCII) solution. When different concentrations of heparin disaccharide were present in the HCII/heparin interaction solution, no competition effect was observed (not shown). In all other cases, increasing concentrations of competing analytes (heparin, LMW heparin, tetrasaccharide, and hexasaccaride) decreased the observed binding of HCII (Fig. 4B-E) . For example, when the concentration of LMW heparin was 10 nM (Fig. 4C) , the interaction decreased to approximately 50% of the control value (no competing analyte present). At a concentration of LMW heparin of 100 nM, virtually no binding was observed. The IC 50 value is commonly defined as the concentration of competing analyte resulting in 50% of response observed in the absence of competing analyte. The IC 50 values for heparin, LMW heparin, tetrasaccharide, and hexasaccaride were calculated from these curves and given in Table 3 .
Effect of Samples on HCII-Mediated
Anti-Thrombin Activity First, heparin was examined for its effect on the HCII-mediated anti-thrombin activity in the presence and absence of added calcium chloride. Surprisingly, 1 mM calcium ion showed no effect on heparin-mediated enhancement of HCII based inhibition of thrombin. Next, HCIImediated thrombin inhibition assay of tetrasaccharide, hexasaccharide, and octasaccharide was performed ( Table 4 ). All three oligosaccharides enhanced HCII-based inhibition of thrombin. The octasaccharide showed 55% of heparin's activity. 
DISCUSSION
HCII selectively inactivates thrombin in a reaction that is accelerated greater than 1000-fold by glycosaminoglycans (GAGs) such as heparin, dermatan sulfate, and heparan sulfate (3). In comparison to antithrombin III (ATIII), HCII features in several important ways (3, 4) : a) HCII only inactivates thrombin, whereas ATIII inactivates other coagulation enzymes including factors Xa and IXa; b) the high-affinity interaction of heparin with ATIII is mediated by a unique pentasaccharide sequence found only in a subpopu-lation of heparin molecules. In contrast, heparin does not possess a high affinity sequence for HCII. c) Dermatan sulfate (DS) activates HCII, but has no effect on ATIII. d) The uncatalyzed rate of thrombin inactivation by ATIII is about 10-fold faster than that for HCII; e) HCII possesses a unique 75-amino acid domain at its amino terminus that binds to thrombin exosite I, an interaction analogous to the binding of the carboxyl terminus of hirudin to exosite I. Although the uncatalyzed rate of thrombin inactivation by HCII is slower than that for ATIII, in the presence of heparin or DS, HCII inactivates thrombin at a rate similar to that at which ATIII inactivates thrombin when heparin is present (4) . Three potential modes of GAG-mediated thrombin inactivation by HCII are proposed (4): a) displacement of the amino terminus of HCII, thereby freeing it to interact with thrombin exosite I; b) bridging of exosite II of thrombin to HCII; and c) induction of conformational changes at the reactive site loop of HCII.
In our current study, the real time SPR kinetics analysis of the interaction between HCII and heparin showed a K d of 3.03 × 10 -6 M, which is comparable to HCII concentration of 1.2 µM in human plasma (3) . When there is calcium ion (1 mM) in the buffer, the measured K d of 2.23 × 10 -7 M indicating heparin/HCII interaction is enhanced by calcium ion to approximately 10fold. Based our amino acid sequence analysis and modeling on HCII, three putative calciumbinding sites observed in the sequence might be responsible for this interaction. The presence of 1 mM calcium ion, however, had no effect on the heparin-mediated enhancement of HCIIbased inactivation of thrombin. Thus, the true physiologic role of calcium in HCII function is still requires additional investigation. Heparin is also known to bind to calcium (17) (18) (19) . Further experiments need to be conducted to see whether calcium enhancement of HCII-heparin interaction is due primarily to heparin-calcium or HCII-calcium binding. A recent, very interesting study by Eckert and Ragg suggests that HCII is a zinc binding protein despite the very low plasma concentration of free Zn 2+ ions (9, 20) . They found that Zn 2+ , but not Ca 2+ , was able to alter the intrinsic fluorescence of HCII. Furthermore, their experiments show that Ca 2+ ions did not increase the salt concentration required to elute HCII from a heparin affinity column. These salt elution experiments demonstrate that higher than physiologic concentrations that Na + ions can displace Ca 2+ ions from HCII bound to heparin.
Calcium might still promote heparin-HCII interaction under physiologic conditions. Furthermore, Ca 2+ is found in high concentrations in the plasma and is observed in the x-ray structure of HCII (21) . Alternatively, Zn 2+ may be the critical cation involved in promoting heparin-HCII interaction, but based on our observation of three EF-hand motifs, we would suggest a divalent cation-binding site close to the C-terminus of HCII. Clearly, based on our observations and those of Eckert and Ragg (9), additional studies are warranted.
Competition studies using heparin-derived oligosaccharides demonstrated that the smallest oligosaccharides size competing with heparin binding to HCII was tetrasaccharide. This is in agreement with results from our laboratory (13) and the HCII-sepharose affinity chromatography results previously reported by Tollefsen (15) . The variation in IC 50 values observed for heparin, LMW heparin, tetrasaccharide, and hexasaccaride confirms that the activation of HCII by heparin is chain-length-dependent, suggesting heparin uses a template mechanism to accelerate the inhibitory process. Furthermore, while very large oligosaccharides are required to bind HCII as tightly as heparin, an octasaccharide showed significant bioactivity.
